A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
National Institutes of Health Clinical Center (CC)
Genmab
Coherus Oncology, Inc.
Revolution Medicines, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
AstraZeneca
Roswell Park Cancer Institute
Pfizer
Merck Sharp & Dohme LLC
City of Hope Medical Center
Tesaro, Inc.
Eli Lilly and Company
Jazz Pharmaceuticals
Incyte Corporation
Toray Industries, Inc
Shanghai Junshi Bioscience Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Eli Lilly and Company
Taiho Pharmaceutical Co., Ltd.
Cantargia AB
Emory University
Canadian Cancer Trials Group
Cantargia AB
Nektar Therapeutics
Incyte Corporation
Holy Name Medical Center, Inc.
American College of Radiology Imaging Network
Eli Lilly and Company
Critical Outcome Technologies Inc.
Masonic Cancer Center, University of Minnesota
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NYU Langone Health
Wuhan University